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SARS-CoV-2

The dynamic changes in cytokine responses in
COVID-19: a snapshot of the current state of
knowledge
“The role of cytokines in COVID-19” online symposium was presented on 18 June 2020 by the NIH/FDA
Immunology and Cytokine Interest Groups and was purposed to discuss our rapidly changing understanding
of COVID-19-related cytokine responses in different stages of infection, including the etiologies, downstream
consequences and possible mitigation strategies. The recording is available at https://nci.rev.vbrick.com/
sharevideo/03106730-66cc-47ba-870b-f6e6274a998a.

T

he symposium was opened by
Anthony Fauci, Director of the
National Institute of Allergy and
Infectious Diseases at the US National
Institutes of Health (NIAID, NIH), and
Janet Woodcock, Director of the Center
of Drug Evaluation and Research, Food
and Drug Administration (CDER, FDA)
and currently leading the therapeutics
component of Operation Warp Speed.
Fauci briefly reviewed the current
status of the coronavirus disease 2019
(COVID-19) pandemic, noting that
the worldwide incidence had grown to
8 million cases and more than 300,000
deaths, with >120,000 fatalities in the USA
alone (incidence on June 18 2020). The
causative virus, the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2),
is a single-stranded RNA virus that uses
angiotensin-converting enzyme 2 (ACE2)
as a cellular receptor. The atomic-level
conformation of the prefusion spike protein
of the virus was recently described by
NIAID Vaccine Research Center scientists
and colleagues1. He also underscored
the role of cytokines in the pathogenesis
of the different clinical presentations of
COVID-19, ranging from asymptomatic to
pneumonia, neurological disorders, acute
respiratory distress syndrome (ARDS),
cardiomyopathies, sepsis, hypercoagulability,
multiorgan failure and death, as well as
the multisystem inflammatory syndrome
seen in children. Also, the benefit of
dexamethasone treatment in severe COVID19 cases requiring ventilation was discussed,
which is consistent with the central roles
of inflammation and a cytokine storm in
causing serious pathology. Fauci ended
his talk by calling attention to the multiple
initiatives undertaken and supported by
the NIAID to address the COVID-19
outbreak. Woodcock followed with an
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address that underscored the broad variety
of clinical presentations of COVID-19,
thus highlighting the central role of the
immune response in this disease. She also
remarked on the apparent geographic
clusters of disease manifestations and the
need to better understand possible factors
in host–pathogen interactions beyond those
health conditions already identified, such
as prior innate immune experience and
subtle differences in ACE2 expression in
the populations. Lastly, she discussed the
complexity of the data emerging from the
multiple clinical trials that are targeting
the inflammatory process underlying the
disease, emphasizing the importance of
establishing clinically relevant biomarkers to
guide the therapeutic course.

Cytokine response and disease severity
The first scientific session of the meeting
focused on the changing cytokine response
over the course of COVID-19 and was
opened by Miriam Merad (Mount Sinai
School of Medicine). Merad first reminded
us that the infection is asymptomatic
in 80% of adults and most children, but
20% of patients require hospitalization
in the intensive care unit (ICU). The
mortality rate for patients in the ICU is
25%, with most deaths attributed to severe
inflammation and embolic complications.
In agreement with Woodcock’s remarks
on the importance of biomarkers to better
target therapeutic efforts, Merad described
studies using high-dimensional profiling to
identify early markers that predict disease
severity. In one study, her group selected
a platform that monitors interleukin (IL)6, IL-8, IL-1β and tumor necrosis factor
(TNF), which are well-established targets
for anti-inflammatory therapeutics. They
tested over 1,500 patients on the day of
hospitalization and then correlated the

serum cytokine concentrations with disease
outcome. Her data showed that IL-6, IL-8
and TNF, and to a lesser extent, IL-1β, were
elevated at the time of hospitalization, and
their concentrations correlated with disease
outcome and mortality, even after correcting
for age, ethnicity, race and comorbidities,
suggesting that they could be used to
identify patients at risk of severe disease2.
The proinflammatory cytokines
remained elevated throughout the disease
course unless patients were treated with
steroids or remdesivir, which reduced
the level of circulating IL-6. She also
stressed that IL-6 and TNF are regulated
independently and thus could be targeted
in parallel in patients with severe disease.
Merad then described early results from
deep-profiling longitudinal studies using
whole-blood proteomics that identified 23
clusters of cytokines that are differentially
expressed in patients with mild disease,
severe disease without end organ damage
and severe disease with end organ damage.
In this broader assessment, patients with
severe disease had increased IL-6 and other
proinflammatory cytokines, while those
with moderate disease had a pattern that
suggested T cell priming. Lastly, Merad
suggested that the pattern of cytokine
response in children with multisystem
inflammatory syndrome partly resembled
that of adults with severe disease, as they had
increased expression of proinflammatory
cytokines; however, they also had a variety
of autoantibodies, including some classical
autoantibodies, but also autoantibodies
directed to cardiac and endothelial
antigens that might explain the disease
manifestations. Importantly, the cytokine
patterns that were present at the time of
hospitalization in children as well as adults
were maintained throughout the disease
course unless modified by treatment with
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steroids, remdesivir or immunomodulatory
therapy and could be correlated with disease
outcome, suggesting that they can be used to
guide the therapeutic approach.
John Tsang (NIAID, NIH) then spoke of
the application of a systems immunology
analysis of COVID-19. He described
studies employing cellular indexing of
transcriptomes and epitopes by sequencing
(CITE-seq), a single-cell analysis method
that combines highly multiplexed surface
protein marker detection with transcriptome
profiling. The Tsang lab and collaborators
evaluated peripheral blood mononuclear
cells (PBMCs) from a longitudinal cohort
of hospitalized patients with COVID-19
from Brescia, Italy, taken at the height of
the outbreak in that region. The patients
evaluated in this first experiment included
13 severe or critical patients and 5 ageand sex-matched healthy controls. Two
observations in particular emerged that
differed from findings reported by other
investigators. First, whereas previous studies
suggested that the virus disrupted the type I
interferon (IFN) signaling pathway, fueling
speculation that the lack of an early type I
(and III) IFN response permits rapid viral
spread and induces hyperinflammatory
responses, this study identified a clear type
I IFN signature across major immune cell
subsets in patients with COVID-19. These
findings suggest that a careful evaluation of
the patient populations scrutinized across
different studies should be performed, as the
timelines for the induction of such responses
may differ according to disease stage and
may be further influenced by genetic
and environmental factors. Furthermore,
thus far, Tsang has found no evidence
of T cell exhaustion, as the expanded
CD8+ T cell clones were found to have
decreased PD-1 expression in comparison
with the non-expanded cells in patients.
This observation again differs from other
studies that found high amounts of PD-1
expression on lymphocytes3, indicating
exhaustion and raising the possibility that
checkpoint blockade should be considered
for treatment.
The final seminar in this session was
given by Frank van de Veerdonk (Radboud
University Medical Center). The main
focus of his seminar regarded unique
aspects of COVID-19 immune pathology;
specifically, the role of ACE2 in modulation
of the kallikrein–kinin system. Preliminary
results suggested that this system has a
role in the angioedema observed in the
lungs of COVID-19 patients. Biological
pathways were evaluated via proteomic
analysis of serum from patients with
severe (necessitating ICU care) versus
more moderate (not requiring ICU care)
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Fig. 1 | Alveolus during severe COVID-19 hyperinflammation. ACE2 downregulation by SARS-CoV-2
is followed by the loss of neutralizing capacity of Lys-[des-Arg9]-bradykinin (BK) in the lung, leading
to plasma leakage. Subsequently, plasma leakage results in more B1R ligands (des-Arg9-BK) and B2R
ligands (bradykinin), enhancing vascular permeability and angioedema. CPM, carboxypeptidase M;
CPN, carboxypeptidase N; HMWK, high-molecular-weight kininogen; LMWK, low-molecular-weight
kininogen. Figure reproduced with permission from ref. 4, eLife Sciences Publications.

disease, with an initial focus on IL-1 biology
and autoinflammation and a subsequent
focus on the kallikrein–kinin system. IL-6
upregulation was prominent in patients
with severe disease, which van de Veerdonk
proposed was a manifestation of the
strong induction of an autoinflammatory
loop via IL-1β and the IL-1 receptor (IL1R). He proposed that, following SARS
CoV-2 binding to pathogen recognition
receptors, pro-IL-1β is induced, processed
to IL-1β by activated inflammasomes and
stimulates IL-6 and IL-18 production
(from pro-IL-18). IL-1β binds to IL-1R on
monocytes/macrophages, generating the
autoinflammatory loop and recruitment
of polymorphonuclear leukocytes. He also
noted that IL-1α released during tissue
damage may further contribute to the
autoinflammatory loop by binding and
signaling through IL-1R, inducing more
IL-1β. He further remarked that IL-1 is
a difficult cytokine to measure (echoing
others) and that concentrations in plasma
likely do not reflect those in the lung,
suggesting that bronchoalveolar lavage
(BAL) measurements would be important
in verifying its upregulation at the site of
primary pathology. Lastly, he remarked on
the substantial reductions in IL-7R and stem
cell factor and their potential relevance to
the commonly observed lymphopenia in
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patients with severe disease, which is of clear
interest from a therapeutic standpoint. In the
last part of his talk, van de Veerdonk focused
on the reduced amounts of serpin family
A member 12 (SERPINA12) and DPP4
(CD26) in patients in the ICU versus those
not in the ICU. Since these factors suppress
inflammation mediated by kallikreins
and it is expected that there is positive,
coordinated stimulation of the kallikrein–
kinin system from increases in IL-1 and
IL-6 as well as from activated complement,
the upregulation of the kallikrein–kinin
system was investigated. Most critically,
kininogens processed by kallikrein, a serine
protease, will generate bradykinin (BK)
or Lys-BK (Fig. 1), which can be further
metabolized by tissue carboxypeptidases,
producing des-Arg9-BK (DABK). DABK
binds to bradykinin 1 receptors (B1Rs) and
enhances vascular permeability, which can
lead to local angioedema. Critically, DABK
is inactivated by ACE2. Because ACE2 is
internalized by SARS-CoV-2, it is no longer
present to counter the downstream effects
of DABK, thus producing angioedema in
the lung, which potentially explains the
early ARDS manifestation in these patients.
Furthermore, IL-1 and inflammation in
general stimulate increased expression of
B1Rs, thus upregulating these receptors in
the inflamed lung and boosting tissue-level
1147
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Fig. 2 | The COVID-19 inflection point of illness. A graphic depiction of the course of illness for the
up-to-20% of individuals with COVID-19 who develop cytokine storm syndrome (CSS) and respiratory
distress requiring hospitalization17. Severity of illness is presented along the y axis and time in days along
the x axis. The participation of both the innate and adaptive immune responses is presented as orange
and green triangles, respectively, during the different phases of disease. The early stages of infection
(<5 days of symptoms) give rise to a more prominent respiratory phase in those with early signs of
CSS, such that an inflection point of illness occurs typically between days 5 and 7 of illness. This interval
is the time in which targeted immunomodulatory therapy will probably be most beneficial in lowering
mortality (dashed arrow). MODS, multiorgan dysfunction syndrome. Figure adapted with permission
from ref. 17, the Journal of Rheumatology Publishing.

angioedema. The ensuing plasma leakage
into the alveolar space allows activation
of plasma kallikrein–kinin at the site
of infection. Subsequent production of
bradykinin results in persistent angioedema
via bradykinin activation of the bradykinin 2
receptor (B2R).
This observation led to the hypothesis
that the kallikrein–kinin system was
critically involved in lung pathology in
COVID-19, which was tested by treating
patients with hypoxia and enhanced oxygen
requirements with icatibant, an approved
B2R blocker for hereditary angioedema
(HAE). Promising effects were observed,
which will be published soon. This finding
suggests the need for expanded trials as well
as the investigation of a longer lasting agent,
lanadelumab, which blocks plasma kallikrein
activity and is approved for HAE. In light
of the findings of this study and data from
other sources, a treatment protocol based on
disease stage was proposed4.

Cellular origins of cytokines

The second session commenced with Chen
Dong (Tsinghua University), who discussed
his recently published work5 on humoral
responses in patients with COVID-19. In
a small cohort, his group readily detected
1148

IgG1 and IgM antibodies that recognized
recombinant SARS-CoV-2 nucleoprotein
and the receptor-binding domain of the
spike protein (S-RBD) in patient sera
as compared to serum from healthy
individuals. In general, antigen-specific
antibody concentrations were higher in
individuals recently released from hospital
(8 patients) as compared to those assayed 2
weeks after release (6 patients). Longitudinal
studies on larger patient cohorts will be
needed to determine the time course and
duration of humoral responses during
COVID-19. Somewhat consistent with
these observations, Luigi Notarangelo
(NIAID, NIH) noted in a study of more
than 300 patients from Brescia and Monza
in northern Italy that the proportion of
plasmablasts in blood was highest in the
early stages of COVID-19 and decreased
with disease course6. Using a pseudovirus
particle-based neutralization assay, Dong
found that 13 out of 14 patients developed
varying levels of neutralizing antibodies with
specificity for S-RBD. In an independent
study, 94% of 175 patients developed
neutralizing antibodies, suggesting that such
humoral responses are a consistent feature
of COVID-197. Importantly, antibody titers
did not correlate with disease duration in

this study, leaving open the question of the
contribution of antibodies in determining
disease progression. It is possible that a
threshold level of antibody synergizes with
other features of immune (for example,
T cell activation and memory formation)
and inflammatory responses to affect
disease resolution. It also remains unclear
to what extent neutralizing antibodies
persist in convalescent individuals and
whether they will protect upon rechallenge
with SARS-CoV-2. In this regard, another
study reported that 40% of asymptomatic
individuals and 13% of symptomatic
individuals became seronegative 8
weeks after discharge from hospital6.
This apparently short-lived antibody
response contrasts sharply with detectable
SARS-CoV-specific IgG 2 years after
infection8.
Notarangelo provided a comprehensive
overview of cellular and cytokine changes
in the context of disease course and severity
in the Italian cohort. A recurring pattern
in COVID-19 is the increased expression
of proinflammatory cytokines such as IL-6,
TNF and IL-1β, as well as an IFN-γ signature
evidenced by expression of the downstream
cytokine CXCL9; similar observations
were also presented by Merad and Tsang
in Session 1. Serum concentrations of
soluble biomarkers of endothelial cell
activation (ICAM-1 and VCAM-1) and of
septic shock (lipopolysaccharide binding
protein (LBP) and sIL-33R) were also
significantly elevated in patients with
COVID-19 and more so in those with
critical disease who eventually died. In
an interesting twist, Notarangelo showed
that, during the course of disease, certain
inflammatory markers, such as IL-6, did not
change significantly, whereas others, such
as soluble IL-33R (sIL-33R) and CXCL10,
decreased in patients who eventually
recovered but remained persistently elevated
in those who succumbed to COVID19. Additionally, cytokines associated
with myeloid differentiation positively
correlated with disease severity, suggesting
a contribution of de novo myelopoiesis.
A striking observation in this study was
the reduced numbers of CD4+ and CD8+
T cells in patients with COVID-19. T
lymphopenia was evident even in patients
with mild symptoms, and it reached extreme
deficits in those with severe disease9. The
underlying cause of T cell loss is not known
and will be an important area of future
research. Notarangelo also pointed out the
surprising decrease in soluble Fas ligand
(sFasL) and sCD62L, contrasting with high
concentrations of sCD25, a biomarker of
T cell activation. A preprint in bioRxiv also
reported profound antigen-specific T cell
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Fig. 3 | IFN-α2b treatment accelerates viral clearance and reduces inflammatory IL-6. Patients with confirmed COVID-19 were treated with either ARB alone
(ARB; 24 patients) or IFN-α2b with or without ARB (IFN; 53 patients). Left, upper respiratory samples were assessed by PCR for the presence of SARS-CoV-2.
Shown is the proportion of patients who had detectable virus as a function of the day of sampling from symptom onset. The P value for treatment effect was
assessed using a Cox proportional-hazards model that included age and comorbidities as covariates. Right, patients were serially sampled for assessment
of IL-6 from the day of symptom onset. Values recorded were aggregated across 3 day intervals and shown as the mean ± s.e. P value was assessed using R
v.3.6.0, and analysis of variance (ANOVA) was used to test for treatment effect, adjusting for age and comorbidities. Figure reproduced with permission from
ref. 15, International Union of Immunological Societies.

activation and cytotoxic responses even in
seronegative individuals7. Further studies are
required to understand the contributions of
such contrasting immune responses to the
course of COVID-19. Finally, Notarangelo
provided evidence that reduced expression
of HLA-DR and CD4 on peripheral blood
monocytes (the former a biomarker of
antigen-presenting capacity) correlated
with disease severity9. By impairing
antigen presentation and the consequent
activation of T cells, this cellular phenotype
could attenuate effective responses during
SARS-CoV-2 infection. The predictive
potential of this biomarker remains to be
determined.
The final speaker in this session, Xiaoyu
Hu (Tsinghua University), elaborated
specifically on the nature and origins of
cytokine responses in COVID-19, focusing
on the lung myeloid compartment of
patients. Previous studies have shown that
the largest population of lung-resident
alveolar macrophages are of fetal origin and
are maintained by proliferation in situ10.
Single-cell RNA sequencing studies of
BAL fluid from patients with COVID-19
showed a substantial influx of peripheral
monocyte-derived macrophages to the
lungs, with a proportionate reduction in
the frequency of alveolar macrophages;
these changes in cell populations correlated

with disease severity11,12. Recruited
macrophages primarily expressed high
amounts of chemokines such as CCL2,
CCL7 and CCL8 and, with increasing
disease severity, CXCL10 and CCL3. By
contrast, typical proinflammatory cytokines
such as IL-6 and IL-8 that were elevated
in the periphery were not markedly
upregulated in these cells. The distinct
lung-specific responses may contribute
to COVID-19 lung pathophysiology, for
example, by CCL2-mediated recruitment of
macrophages11.
The basis for the dichotomy between
the chemokine-dominated lung
macrophage response and the peripheral
prevalence of more classical inflammatory
cytokines is not clear. One possibility is
that the lung microenvironment skews
macrophage responses toward chemokine
gene expression. In this scenario, lung
macrophage responses in other acute
respiratory syndromes should also be
similarly skewed. However, it should be
noted that resident alveolar macrophages
do not exhibit this pattern, indicating
that it is not solely a microenvironment
issue. Alternatively, SARS-CoV-2 infection
may generate a unique inflammatory
milieu that promotes the observed gene
expression pattern. That it is restricted
to recruited macrophages hints at a role
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for peripheral priming in generating the
phenotype.

Cytokine-targeted mitigation
strategies

The symposium concluded with a session
that discussed the recent advances in
managing both the virus infection and the
associated cytokine storm using biologics
and drugs to treat the disease and how
such approaches significantly ameliorated
disease outcomes. Randy Cron (University
of Alabama at Birmingham) started off this
session by reminding us that, long before
COVID-19 came into the limelight, the
cytokine storm was already recognized
as a major issue in the field of immune
homeostasis. Cytokine storm is an umbrella
term for several hyperinflammatory
immune responses that include cytokine
release syndrome, culture-negative sepsis,
macrophage activation syndrome and
hemophagocytic lymphohistiocytosis
(HLH), among others. Therefore, there are
several causes of cytokine storm, which can
be triggered by genetic factors, cancer, viral
infections and other insults and that need to
be managed accordingly. Consequently, the
COVID-19-triggered cytokine storm should
be manageable using knowledge amassed
in the past based on the management of
similar viral infections (Fig. 2). In the course
1149
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of his brief but cutting-edge overview of
the literature, Cron cited a previous study
wherein the inability of perforin-deficient
CD8+ CTLs to eliminate LCMV-infected
target cells resulted in the death of infected
mice by hyperactivation, but not when
IFN-γ was neutralized13.
Along these lines, the disruption of other
genes involved in the cytolytic pathway
also results in a cytokine storm and lethal
hyperinflammation. For example, the
Cron group performed whole-exome
sequencing of patients who succumbed to
H1N1 influenza infection and found that
36% of the 14 individuals in the study had
mutations in the genes encoding either
perforin or the lysosomal trafficking
regulator (LYST). Thus, cytokine storm is
evidently associated with the failure to clear
virus-infected target cells and persistent
T cell stimulation. As a solution, Cron
summarized a few approaches focused
on targeting IL-6, IL-1 or JAK/STAT
proteins to suppress the cytokine storm. He
concluded his talk by offering alternative
strategies to reduce hyperinflammation,
such as JAK inhibitors and glucocorticoids.
Specifically, the World Health Organization
initially recommended against the use of
corticosteroids for COVID-19 based on the
experiences of SARS and MERS, but recent
data showed a clear reduction in the need for
ventilation and in mortality in patients with
COVID-19 treated with dexamethasone14.
Steroids are widely available and affordable,
and, with careful dosing and timing, these
agents could become powerful tools in
fighting the cytokine storm triggered by
SARS-CoV-2.
In the next seminar, Eleanor Fish
(University of Toronto) put the COVID19 pandemic into greater perspective
by pointing out two other coronavirus
outbreaks that had preceded SARS-CoV-2,
namely SARS-CoV in 2002 and MERS-CoV
in 2012. To control viral infections, the first
24–72 hours are the most critical, and Fish
emphasized that the type I IFN response
by innate cells plays a pivotal role in this
process. Type I IFNs are powerful because
they not only act directly on infected cells
to suppress viral replication but also recruit
and activate immune cells to clear the virus.
Notably, the SARS-CoV-2 genome encodes
genes that suppresses IFN production, such
as Nsp1, Nsp3, ORF6 and the M proteins.
Thus, it is evident that viruses are equipped
with tools to dampen host IFN production,
and both SARS-CoV-2 and SARS-CoV fail
to trigger a good type I IFN response.
Along these lines, the Fish group
demonstrated that SARS-CoV replication
in vitro could be effectively suppressed
by IFN alfacon-1 treatment (a synthetic
1150

IFN-α) and that such an effect was further
reproduced in a clinical trial when SARS
patients were subcutaneously injected
with IFN alfacon-1, resulting in rapid lung
clearance and substantial improvements
in various clinical parameters. Translating
those findings to COVID-19, a clinical trial
was designed involving 77 hospitalized
patients with confirmed cases of COVID19 in Wuhan, China. In this trial, patients
were treated with either the antiviral drug
arbidol (ARB), nebulized IFN-α2b or a
combination of the two agents. While the
investigators did not observe any differences
among patients in the treatment groups
with respect to body temperature, oxygen
saturation or blood biochemistry, there was
a significant difference in viral clearance, as
IFN-treated patients cleared the virus much
faster. Notably, IFN-treated patients also
showed significantly reduced concentrations
of serum IL-6 and C-reactive protein (CRP)
(Fig. 3)15. Thus, with the caveat that this trial
was a non-randomized, small-cohort study,
the data advocated for using type I IFN as
an early intervention agent in COVID-19.
Moreover, type I IFN treatment may prove
to be more beneficial than other treatments
because it did not trigger a cytokine storm
or severe adverse events. Furthermore, it
may be advantageous over treatment with
type III IFN, given the systemic spread
of SARS-CoV-2 from the lungs to the
vasculature and other organs, as type I IFN
receptors are expressed on virtually all cells,
whereas type III IFN receptor expression is
largely restricted to epithelial cells.
Michail Lionakis (NIAID, NIH)
presented his recent work utilizing a kinase
inhibitor to antagonize the COVID-19
cytokine storm16. The hyperinflammatory
response in COVID-19 features activation
of NF-κB and the inflammasome (Nlrp3),
as evidenced by the increased levels of
proinflammatory cytokines and chemokines,
including IL-1β, TNF, IL-6, CCL2 and
CCL3, among others. Consequently, he
hypothesized that neutralizing these
cytokines or their downstream signaling
would be an effective strategy to suppress
the COVID-19-associated cytokine storm.
Using mouse models of Bruton’s
tyrosine kinase (BTK) deficiency and
pharmacological inhibitors of BTK, the
Lionakis group previously pinpointed the
target population of BTK inhibition in
antifungal host defense to be macrophages,
not B cells. Ibrutinib is an effective and
well-tolerated BTK inhibitor that blocks
B cell receptor signaling and is used
as a treatment for B cell malignancies
and inflammatory conditions such as
graft-versus-host disease. Thus, the
suppression of macrophages has been

considered a collateral effect of BTK
inhibition, resulting in impaired fungal
immunity as demonstrated by the
susceptibility to fungal infections in
a subset of ibrutinib-treated patients.
Notably, ibrutinib has been reported to
suppress macrophages by inhibiting the
activation of both the inflammasome and
NF-κB, precisely the two downstream
pathways of the cytokine storm in severe
COVID-19. These findings led Lionakis
and his colleagues to hypothesize
that BTK inhibitors would ameliorate
hyperinflammation and thus prevent
clinical deterioration in patients with
severe COVID-19. The Lionakis group
hypothesized that the overt immune
response of SARS-CoV-2-infected alveolar
macrophages could be inhibited at the
proximal signaling level by the off-label
use of a second generation BTK inhibitor,
acalabrutinib. Such an approach could
be superior to employing neutralizing
antibodies specific to individual
proinflammatory cytokines because it could
potentially suppress the effect of multiple
cytokines. In addition, because BTK is not
expressed in T cells, BTK inhibition would
limit the effect to macrophages without
impacting anti-viral T cell effector function.
The results from the first clinical study
with 19 patients were in line with the
hypothesis, and some remarkable effects
were observed for patients with COVID19 in the pre-ICU setting16. While patients
with severe COVID-19 symptoms had
increased production of IL-6 by CD14+
monocytes in blood, acalabrutinib
treatment substantially improved
oxygenation, decreased inflammation
(for example, reduced production of CRP
and IL-6) and also significantly increased
lymphocyte numbers in the majority of
patients. Mechanistically, it was found
that monocytes but not B cells in patients
with COVID-19 contained higher basal
levels of phosphorylated BTK, validating
that monocyte/macrophage-directed
BTK inhibition provides the basis of
suppressing the cytokine storm14. Currently,
three different BTK inhibitors, including
acalabrutinib, zanubrutinib and ibrutinib,
are in clinical trials for treatment of severe
COVID-19. Further studies will be required
to validate these clinical findings, which,
if confirmed, would potentially point to a
broader use for BTK inhibitors in managing
hyperinflammatory responses.
Collectively, the talks in this session
highlighted the multifaceted approaches
to neutralize cytokine storm in patients
with COVID-19, and they showcased
initial successes. Moreover, the results
further illustrated the necessity of nimble
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approaches in applying interventional
strategies, depending on the severity or stage
of the diseases. Thus, the dosing, timing
and the selection of the patient group must
be considered carefully and in the context
of disease progression. Dexamethasone
treatment, for example, should be reserved
for late-stage patients because of its
immunosuppressive function, whereas type
I IFNs are clearly suitable for investigation
in immediate early treatment. Targeted
suppression of immune cell activities by
BTK inhibitors has been tested in patients
requiring oxygen supplementation, but it
remains unclear whether treatment at earlier
stages would be even more effective.

Concluding remarks

This conference brought together over
1,600 scientists from different countries
and different time zones, demonstrating the
power of running a virtual conference but
also documenting the immense worldwide
interest in COVID-19 biology. Because of its
great success and the enthusiastic feedback
that was received, the next COVID-19
conference organized by the NIH/FDA
Immunology Interest Group and Cytokine
Interest Group is already being scheduled,
and we look forward to broad participation
in cyberspace in November 2020 to share
the newest and most exciting research

on COVID-19 with the international
community.
Maja Buszko1, Jung-Hyun Park 2,
Daniela Verthelyi 3, Ranjan Sen4,
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